Monitoring anti-inflammatory therapies in patients with atherosclerosis: FDG PET emerges as the method of choice

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 3, 2012, Pages 396-398

  Hacker, M ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CALCIUM; FLUORODEOXYGLUCOSE F 18;

ABDOMINAL SUBCUTANEOUS FAT; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CANCER PATIENT; COHORT ANALYSIS; CORONARY ARTERY; DISEASE MARKER; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IMAGE ANALYSIS; NOTE; OPEN STUDY; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; RISK FACTOR;

ABDOMINAL FAT; ANTI-INFLAMMATORY AGENTS; ARTERITIS; FEMALE; HEPTANOIC ACIDS; HUMANS; MALE; PYRROLES; VASCULAR CALCIFICATION;

EID: 84859646907     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-2027-2     Document Type: Note

References (27)

1. Weintraub HS. Identifying the vulnerable patient with rupture-prone plaque. Am J Cardiol. 2008;101:3F-10F.
2. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25-e146.
3. Naghavi M, Libby P, Falk E, CasscellsSW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation. 2003;108:1772-8. (Pubitemid 37296082)
4. Izquierdo-Garcia D, Davies JR, Graves MJ, Rudd JH, Gillard JH, Weissberg PL, et al. Comparison ofmethods formagnetic resonance-guided [18-F]fluorodeoxyglucose positron emission tomography in human carotid arteries: reproducibility, partial volume correction, and correlation between methods. Stroke. 2009;40:86-93
5. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-95.
6. Rudd JH, Myers KS, Bansilal S, Machac J, Rafique A, Farkouh M, et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007;50:892-6. (Pubitemid 47268746)
7. Naghavi M, Libby P, Falk E, CasscellsSW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation. 2003;108:1664-72. (Pubitemid 37243650)
8. Saam T, Hatsukami TS, Takaya N, Chu B, Underhill H, Kerwin WS, et al. The vulnerable, or high-risk, atherosclerotic plaque: noninvasive MR imaging for characterization and assessment. Radiology. 2007;244:64-77. (Pubitemid 46981959)
9. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105:2708-11. (Pubitemid 34615139)
10. Ogawa M, Ishino S, Mukai T, Asano D, Teramoto N, Watabe H, et al. (18)F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. J Nucl Med. 2004;45:1245-50. (Pubitemid 47611672)
11. Davies JR, Rudd JH, Fryer TD, Graves MJ, Clark JC, Kirkpatrick PJ, et al. Identification of culprit lesions after transient ischemic attack by combined 18F fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging. Stroke. 2005;36:2642-7.
12. Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol. 2006;48:1818-24. (Pubitemid 44648622)
13. Ben-Haim S, Kupzov E, Tamir A, Israel O. Evaluation of 18F-FDG uptake and arterial wall calcifications using 18F-FDG PET/CT. J Nucl Med. 2004;45:1816-21. (Pubitemid 47618437)
14. Bural GG, Torigian DA, Chamroonrat W, Houseni M, Chen W, Basu S, et al. FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging. 2008;35:562-9. (Pubitemid 351674338)
15. Rominger A, Saam T, Wolpers S, Cyran CC, Schmidt M, Foerster S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med. 2009;50:1611-20.
16. Ogawa M, Magata Y, Kato T, Hatano K, Ishino S, Mukai T, et al. Application of 18F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques. J Nucl Med. 2006;47:1845-50. (Pubitemid 47545007)
17. Worthley SG, Zhang ZY, Machac J, Helft G, Tang C, Liew GY, et al. In vivo non-invasive serial monitoring of FDG-PET progression and regression in a rabbit model of atherosclerosis. Int J Cardiovasc Imaging. 2009;25:251-7.
18. Zhao Y, Kuge Y, Zhao S, Strauss HW, Blankenberg FG, Tamaki N. Prolonged high-fat feeding enhances aortic 18F-FDG and 99mTc-annexin A5 uptake in apolipoprotein E-deficient and wild-type C57BL/6J mice. J Nucl Med. 2008;49:1707-14.
19. Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol. 2006;48:1825-31. (Pubitemid 44648621)
20. Wu YW, Kao HL, Huang CL, Chen MF, Lin LY, et al. The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers. Eur J Nucl Med Mol Imaging. 2011. doi:10.1007/s00259-011-1994-7.
21. Budoff MJ, Shaw LJ, Liu ST, Weinstein SR, Mosler TP, Tseng PH, et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol. 2007;49:1860-70. (Pubitemid 46661110)
22. Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358:1336-45. (Pubitemid 351468410)
23. Shaw LJ, Raggi P, Schisterman E, Berman DS, Callister TQ. Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality. Radiology. 2003;228:826-33. (Pubitemid 37025495)
24. Uebleis C, Becker A, Griesshammer I, Cumming P, Becker C, Schmidt M, et al. Stable coronary artery disease: prognostic value of myocardial perfusion SPECT in relation to coronary calcium scoring - long-term follow-up. Radiology. 2009;252:682-90.
25. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;116:39-48. (Pubitemid 47016245)
26. Rosito GA, Massaro JM, Hoffmann U, Ruberg FL, Mahabadi AA, Vasan RS, et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation. 2008;117:605-13.
27. Saam T, Rominger A, Wolpers S, Nikolaou K, Rist C, Greif M, et al. Association of inflammation of the left anterior descending coronary artery with cardiovascular risk factors, plaque burden and pericardial fat volume: a PET/CT study. Eur J Nucl Med Mol Imaging. 2010;37:1203-12.